Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population

Jonas L. Isaksen, Anders Gaarsdal Holst, Adrian Pietersen, Jonas Bille Nielsen, Claus Graff, Jørgen K Kanters

Research output: Contribution to journalJournal articleResearch

11 Downloads (Pure)

Abstract

Background: Chloroquine (CQ) and Hydroxychloroquine (HCQ) have recently been suggested as treatment for the current Corona Virus Disease 2019 (COVID-19) pandemic. However, despite their long-term use and only few case reports on adverse effects, CQ and HCQ are listed as a known risk of the lethal ventricular arrhythmia Torsade de Pointes and their cardiac safety profile is being questioned. Thus, we aimed to investigate the electrocardiographic and mortality effects of CQ and HCQ in a primary care population. Methods: We used Danish health care registers and electrocardiograms (ECGs) from primary care to define three studies. 1) A paired study of subjects with ECGs before and during use of CQ/HCQ, 2) a matched ECG study of subjects taking CQ/HCQ compared to controls, and 3) a mortality study on people taking HCQ matched to control. In both matched studies, we adjusted for connective tissue diseases, use of QT-prolonging drugs, and cardiac disease. We used the QTc interval as the marker for electrocardiographic safety. In the mortality study, cases were followed from first claimed prescription until 300 days after estimated completion of the last prescription. 95% confidence intervals follow estimates in parenthesis. Results: Use of CQ was associated with a 5.5 (0.7;10) ms increase in QTc in the paired study (n=10). In the matched study (n=28, controls=280), QTc was insignificantly increased in subjects taking CQ by 4.7 (-3.4;13) ms. With a ΔQTc of 1.0 (-5.6;7.5), use of HCQ was not associated with an increased QTc in the paired study (n=32). In the matched study (n=172, controls=1,720), QTc also was not different between groups (p=0.5). In the mortality study (n=3,368), use of HCQ was associated with a hazard ratio of 0.67 (0.43;1.05). Conclusions: In subjects free of COVID-19, we found a small increase in QTc associated with use of chloroquine, but not hydroxychloroquine. We found no increased mortality associated with use of hydroxychloroquine.
Original languageEnglish
JournalmedRxiv
DOIs
Publication statusPublished - 22 Jun 2020

Keywords

  • COVID-19
  • covid19
  • Chloroquine
  • Hydroxychloroquine
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population'. Together they form a unique fingerprint.
  • Covid-19

    Graff, C.

    01/03/2020 → …

    Project: Research

  • The CGPL Study

    Graff, C.

    01/02/2011 → …

    Project: Research

    File

Cite this